Article

Management of clinical stage I nonseminomatous germ-cell testis tumors.

Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
Expert Review of Anti-infective Therapy (impact factor: 2.65). 03/2003; 3(1):21-30. DOI:10.1586/14737140.3.1.21 pp.21-30
Source: PubMed

ABSTRACT Nonseminomatous germ-cell tumors of the testis, the most common cancer in young adult males, are highly curable. Clinical Stage I disease represents almost a third of the patients. Three treatment strategies are currently available: surveillance, postorchiectomy chemotherapy and retroperitoneal lymph node dissection. Factors predictive of extratesticular involvement have been described, thus making it possible to tailor treatment to risk. New imaging procedures also permit staging and prediction of outcome. Decision-making is shared between the patient and his oncologist. Economic issues are better understood but should be further studied.

0 0
 · 
0 Bookmarks
 · 
14 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

Economic issues
 
Factors predictive
 
New imaging procedures
 
Nonseminomatous germ-cell tumors
 
possible
 
postorchiectomy chemotherapy
 
retroperitoneal lymph node dissection
 
tailor treatment
 
treatment strategies
 
young adult males